2025-05-08T14:45:36-05:00 2024-06-30 431985162 SMITH SULLIVAN & BROWN PC 80 FLANDERS ROAD SUITE 302 WESTBOROUGH MA 01581 990 2023-07-01 471981973 COHEN VETERANS BIOSCIENCE INC COHE 6469704325 82 WENDELL AVENUE 100 PITTSFIELD MA 01201 MAGALI HAAS MD PHD BOARD CHAIR 6469704325 2025-05-08 1 1 SANDRA M BROWN CPA P01614103 5088717178 2025-05-08 2023 2025-03-06 01:10:19Z MAGALI HAAS MD PHD 82 WENDELL AVENUE 100 PITTSFIELD MA 01201 8377751 0 X WWW.COHENVETERANSBIOSCIENCE.ORG X 2014 MA BIOMEDICAL RESEARCH AND TECHNOLOGY ORGANIZATION DEDICATED TO ADVANCING BRAIN HEALTH BY FAST-TRACKING PRECISION DIAGNOSTICS AND TAILORED THERAPEUTICS. 5 4 29 25 0 0 10755381 8131591 0 0 223966 51935 364187 194225 11343534 8377751 198197 31373 0 0 6759744 8107509 0 0 329114 8383425 5941028 15341366 14079910 -3997832 -5702159 11743398 3075275 3853705 3105844 7889693 -30569 X COHEN VETERANS BIOSCIENCE, INC. IS A NON-PROFIT 501(C)(3) BIOMEDICAL RESEARCH AND TECHNOLOGY ORGANIZATION DEDICATED TO ADVANCING BRAIN HEALTH BY FAST-TRACKING PRECISION DIAGNOSTICS AND TAILORED THERAPEUTICS. 0 1 11846371 31373 BRAIN HEALTH TOOLS & TECHNOLOGIES:IN ORDER TO FAST-TRACK PRECISION DIAGNOSTICS AND TARGETED THERAPEUTICS AND WELLNESS APPROACHES FOR MAINTENANCE AND RESTORATION OF BRAIN HEALTH, CVB IS LEVERAGING INNOVATION AND TECHNOLOGY TO BUILD TOOLS AND PLATFORMS THAT ENABLE DISCOVERY AND DEVELOPMENT ACROSS BRAIN DISEASES. THESE TOOLS & PLATFORMS ALLOW RESEARCHERS FROM ACADEMIA AND INDUSTRY TO ACCESS AND UTILIZE BEST-IN-CLASS PRACTICES AND ALLOW EFFORTS TO BE SCALED WITH RIGOR AND REPRODUCIBILITY.OUR PLATFORM PROGRAMS CURRENTLY INCLUDE THE BRAINCOMMONS (CLOUD-BASED DATA & ANALYTICS), EARLYSIGNAL (WEARABLE AND HOME SENSORS FOR MONITORING HEALTH STATUS), RAPID-DX (ESTABLISHING BEST PRACTICES FOR DISCOVERY AND VALIDATION OF BIOMARKERS), AMP-IT-UP (FOR PRECLINICAL DISCOVERY AND TRANSLATION) AND TAP (TARGET ADVANCEMENT PROGRAM).BRAINCOMMONSTM:THE BRAINCOMMONS (BC) IS A CLOUD-BASED RESEARCH AND DISCOVERY PLATFORM FOR THE BRAIN HEALTH COMMUNITY WHICH FEATURES DATA, TOOLS, AND COMMUNITY ACCESS IN A SECURE, SCALABLE, AND SUSTAINABLE ENVIRONMENT. IT IS DESIGNED TO FURTHER DEMOCRATIZE DATA AND ENABLE GREATER COLLABORATION GLOBALLY AMONG BRAIN SCIENTISTS WORKING IN A VARIETY OF SETTINGS.EARLYSIGNALTM:THE AIM OF OUR DIGITAL HEALTH PROGRAM, EARLY SIGNAL, IS TO RECORD AND ANALYZE A RANGE OF DATA DIRECTLY RELATED TO THE WELL-BEING OF PATIENTS LIVING WITH BRAIN DISORDERS. BEHAVIORAL, COGNITIVE, PHYSIOLOGICAL AND OTHER INFORMATION ARE COLLECTED THROUGH OUR INTEGRATED TECHNOLOGY PLATFORM IN SUPPORT OF PTSD AND TBI RESEARCH.BRAIN TRAUMA PROGRAMS: POST TRAUMATIC STRESS DISORDER AND TRAUMATIC BRAIN INJURYTHIS CVB PROGRAM WAS FOUNDED IN 2015 TO ESTABLISH A NATIONAL RESEARCH ROADMAP FOR PTSD, TBI AND RELATED CONDITIONS (E.G. SUICIDALITY). IN 2023 WE LAUNCHED THE TBI ACTION ALLIANCE TO SUPPORT THE EXECUTION OF THE NATIONAL TBI ROADMAP THROUGH A PUBLIC-PRIVATE PARTNERSHIP MODEL THAT ENGAGES MULTIPLE SECTORS TO ADVANCE THE OBJECTIVES OUTLINED IN THE ROADMAP AND IN 2024 WE LAUNCHED SUPPORTED ADVCACY, AWARENESS AND RESEARCH CAMPAIGNS AS AN ALLIANCE. (TBIACTION.ORG)NATIONAL NORMATIVE NEUROIMAGING LIBRARY PROGRAM:CVB HAS CREATED AN IMAGING REFERENCE LIBRARY ESSENTIAL TO THE DEVELOPMENT OF EFFECTIVE CLINICAL IMAGING TOOLS FOR DIAGNOSING AND MANAGING PATIENTS WITH BRAIN DISORDERS. ADVANCED NEUROIMAGING CAN NOW DETECT MICROSCOPIC CHANGES IN BRAIN STRUCTURE CAUSED BY TRAUMA OR DISEASE. THESE ADVANCED IMAGING APPROACHES INCLUDE DIFFUSION TENSOR IMAGING ("DTI"), FUNCTIONAL CONNECTIVITY, PERFUSION WEIGHTED IMAGING, AND VOLUMETRIC IMAGING. DESPITE THEIR PROMISE, THESE ADVANCED APPROACHES ARE CURRENTLY PRIMARILY CONFINED TO RESEARCH USE. THE NUMERICAL NATURE OF THE INFORMATION THESE ADVANCED IMAGING APPROACHES YIELD IS DIFFICULT TO TRANSLATE FROM THE STUDY OF GROUPS OF INDIVIDUALS TO A SINGLE PATIENT WITHOUT A REFERENCE. THE IMAGING DATABASE IS BASED ON THE RESULTS OF A NATIONAL STUDY OF NORMATIVE INDIVIDUALS, SPONSORED BY CVB AT UNIVERSITY OF VIRGINIA, BAYLOR UNIVERSITY AND UNIVERSITY OF UTAH AND TWO MILITARY SITES. STANDARDIZED ADVANCED NEUROIMAGING SCANS ON 3,000 ADULT VOLUNTEERS, THE RESULTING IMAGING DATA, ALONG WITH DEMOGRAPHIC INFORMATION AND THE RESULTS OF NEUROCOGNITIVE ASSESSMENTS, IS FORMING A LIBRARY DOCUMENTING POPULATION VARIATION IN BRAIN STRUCTURE AND FUNCTION AS MEASURED BY THESE ADVANCED IMAGING METHODS.THROUGH THIS IMAGING DATABASE, IT IS OUR GOAL TO ADVANCE NEUROIMAGING TO DRAMATICALLY IMPROVE THE IDENTIFICATION OF AFFECTED INDIVIDUALS AND ALLOW PHYSICIANS TO OBJECTIVELY AND EFFICIENTLY DIAGNOSE CONDITIONS SUCH AS TBI, DEMENTIA AND OTHER BRAIN DISORDERS WHERE BRAIN STRUCTURE IS DETECTED VIA MRI.IN 2024, WE PUBLISHED A REPORT OF THE FIRST 1800 ENROLLED SUBJECTS IN THE JOURNAL OF NEUROTRAUMA.PRISM2 (PSYCHIATRIC RATINGS USING INTERMEDIATE STRATIFIED MARKERS 2):IN 2024, THE PRISM2 STUDY PROGRAM WAS COMPLETED WITH THE INNOVATIVE MEDICINES INITIATIVE AND EUROPEAN FEDERATION OF PHARMACEUTICAL INDUSTRIES AND ASSOCIATIONS (EFPIA). THE PRISM 2 (PSYCHIATRIC RATINGS USING INTERMEDIATE STRATIFIED MARKERS 2) PROJECT AIMS TO IDENTIFY QUANTITATIVE BIOLOGICAL FEATURES COMMON ACROSS DEMENTIA, SCHIZOPHRENIA AND MAJOR DEPRESSION, OPENING THE POSSIBILITY OF DEVELOPING TARGETED TREATMENTS IRRESPECTIVE OF TRADITIONAL DIAGNOSIS. THE STATE OF THE SCIENCE SUMMITS ARE THE BASIS FOR BUILDING THE ROADMAPS AND ARE DESIGNED AS RETREATS FOR 100 TO 200 STAKEHOLDERS TO COME TOGETHER TO REALIZE TRUE IMPACT. THE STAKEHOLDERS ENCOMPASS A BROAD SWATH OF THE COMMUNITY FROM ACADEMIC INSTITUTIONS TO GOVERNMENT AGENCIES, FOUNDATIONS SUPPORTING TRANSLATIONAL RESEARCH, INDUSTRY AND INDIVIDUALS WITH LIVED EXPERIENCE.EACH SUMMIT SERVES AS A LAUNCHPAD FOR ONGOING WORKING GROUPS TO DEVELOP EVIDENCE-BASED STRATEGIES AND RECOMMENDATIONS ON HOW TO FILL THOSE GAPS, IDENTIFY NEW GAPS AS OTHERS ARE FILLED, AND DISSEMINATE THESE FINDINGS BACK TO THE COMMUNITY AT LARGE THROUGH WHITE PAPERS AND PROCEEDINGS.THE INAUGURAL STATE OF THE SCIENCE SUMMIT ("SOSS"), HELD IN 2018, FOCUSED ON DIAGNOSIS OF TRAUMA-RELATED BRAIN DISORDERS WITH A MAJOR FOCUS ON POST-TRAUMATIC STRESS DISORDER. THE TRAUMA-RELATED BRAIN DISORDERS RESEARCH COMMUNITY HAS IDENTIFIED A NEED TO ESTABLISH A MECHANISM-BASED TAXONOMY FOR THESE CONDITIONS TO ADVANCE BIOMARKER DISCOVERY AS WELL AS DIAGNOSIS AND THERAPEUTIC DEVELOPMENT. A SHIFT FROM A SYNDROMIC CLASSIFICATION SYSTEM TO A MECHANISTIC ONE NECESSITATES A REVIEW OF THE CURRENT SCIENTIFIC KNOWLEDGE, ADOPTION OF NEW SCIENTIFIC MODELS, AND IDENTIFICATION OF RESEARCH AND KNOWLEDGE GAPS. THE SOSS BROUGHT TOGETHER MULTIDISCIPLINARY STAKEHOLDERS WITH DEEP SCIENTIFIC AND CLINICAL EXPERTISE TO ADDRESS THIS PRESSING NEED.THE THEME OF THE SECOND STATE OF THE SCIENCE SUMMIT, HELD IN 2019 WAS PATHS TO TREATMENT FOR TRAUMATIC BRAIN INJURY(S) WITH A FOCUS ON THE TAXONOMY AND NOSOLOGY OF THE CHRONIC SEQUELAE, CHALLENGES AND OPPORTUNITIES IN CLINICAL PRACTICE AND DEVELOPMENT, AND ETIOLOGY AND MECHANISM OF PERSISTENT SYMPTOMS. AS MEASUREMENT TOOLS ADVANCE, RESEARCH HAS BEEN ABLE TO FOCUS ON DIFFERENT TYPES OF INJURY, BEYOND THE MILD, MODERATE, AND SEVERE CLASSIFICATIONS OF TBI. TO AUGMENT AND SUPPORT THE MANY EFFORTS ACROSS FIELDS AND ORGANIZATIONS OVER THE PAST DECADE, IN 2020 WE WORKED WITH THOUGHT LEADERS ACROSS TBI TO PREPARE A CONSENSUS BLUEPRINT TO DRIVE TRANSLATIONAL SCIENCE FOR TBI. IN 2021, WE PUBLISHED RECOMMENDATIONS IN SUPPORT OF THE NATIONAL TBI PRECISION RESEARCH ROADMAP.IN 2022, WE LAUNCHED THE TBI ACTION ALLIANCE IN SUPPORT OF A NATIONAL TBI PRECISION RESEARCH ROADMAP. THE ROADMAP, BASED ON RECOMMENDATIONS FROM THE BRAIN TRAUMA EXPERT COMMUNITY, OUTLINES A SERIES OF CRITICAL PROJECTS WITH SPECIFIED MILESTONES THAT WILL MATERIALLY ADVANCE PROGRESS TOWARDS THE STATED GOALS OF "ADVANCING A FIRST GENERATION OF TBI DIAGNOSTICS AND TREATMENTS".THE TBI PRECISION RESEARCH ROADMAP FOCUSES ON 7 LINES OF EFFORT:1. INJURY BURDEN: IDENTIFY THE BURDEN OF DISEASE ACROSS ALL POPULATIONS AND INJURY SEVERITIES AS DETERMINED BY INCIDENCE, PREVALENCE AND LONG-TERM TRAJECTORIES OF PATIENTS SUFFERING FROM TBI.2. DISEASE MODELS: DEVELOP AN ARRAY OF TRANSLATIONALLY VALID DISEASE MODELS (PRECLINICAL AND COMPUTATIONAL) BASED ON BIOLOGICAL UNDERSTANDING OF TRAUMA PATHOGENESIS AND DISEASE PHENOTYPES THAT SUPPORT EVALUATION OF NOVEL THERAPIES.3. PRECISION DIAGNOSIS: IDENTIFY, DEVELOP AND VALIDATE DIAGNOSTIC, PROGNOSTIC AND PREDICTIVE BIOMARKERS FORTBI TO DEVELOP FIRST GENERATION DIAGNOSTIC TESTS.4. TARGETED THERAPEUTICS: VALIDATE THERAPEUTIC TARGETS & FAST TRACK A FIRST-GENERATION OF TBI (WELLNESS, DEVICE, DIGITAL, DRUG) THERAPEUTICS TARGETED TO THE RIGHT PERSON AT THE RIGHT TIME.5. CLINICAL PRACTICE IMPLEMENTATION: ACCELERATE ADOPTION OF BEST PRACTICES, CLINICAL PRACTICE GUIDELINES, AND PRECISION THERAPEUTIC APPROACHES TO OPTIMIZE BRAIN HEALTH OUTCOMES.6. TRANSLATIONAL INFRASTRUCTURE AND ENABLINGTECHNOLOGIES: IDENTIFY AND ADDRESS INFRASTRUCTURE,INCENTIVES, REGULATORY AND TECHNOLOGY GAPS TO ADVANCE THE TBI ROADMAP.7. AWARENESS AND ADVOCACY: PLACE TBI AT THE TOP OF THE U.S. PUBLIC POLICY AGENDA AND RAISE AWARENESS TO REDUCE STIGMA OF BRAIN INJURY, ENCOURAGE TREATMENT-SEEKING, AND ENABLE ACCESS AND REIMBURSEMENT OF CARE.IN 2023 WE LAUNCHED THE TBI ACTION ALLIANCE TO SUPPORT THE EXECUTION OF THE NATIONAL TBI ROADMAP THROUGH A PUBLIC-PRIVATE PARTNERSHIP MODEL THAT ENGAGES MULTIPLE SECTORS TO ADVANCE THE OBJECTIVES OUTLINED IN THE ROADMAP. (TBIACTION.ORG)RAPID-DIAGNOSTICS (RAPID-DX) - RESEARCH STUDIES:BEST BIOMARKER PTSD STUDY:DESPITE THE EFFICACY OF PSYCHOTHERAPY AS FIRST-LINE TREATMENT FOR PTSD, LARGE INTER-INDIVIDUAL DIFFERENCES IN OUTCOMES EXIST, WITH ROUGHLY 50% OF PATIENTS RESPONDING TO TREATMENT AND FEWER THAN THAT FULLY REMITTING. THIS GRANT SUPPORTED THE DEVELOPMENT OF A RESPONSE DIAGNOSTIC TEST BASED ON PRELIMINARY FINDINGS FOR A COMBINATION COGNITIVE/IMAGING MARKER RESULTING FROM CVB'S INVESTMENT IN THE COHEN VETERANS CENTER STUDY AT NYU/STANFORD. THE PROGRAM INCLUDED A CLINICAL STUDY AT TWO CENTERS OF OVER 200 SUBJECTS TO REPLICATE THE INITIAL FINDING, AND IS SEEKING QUALIFICATION VIA THE FOOD AND DRUG ADMINISTRATION ("FDA") GUIDANCE TO SUPPORT THE COMMERCIALIZATION AND/OR AVAILABILITY OF THE TEST FOR CLINICAL PRACTICE AND RESEARCH AND DEVELOPMENT. THIS STUDY COMPLETED RECRUITMENT IN DECEMBER 2019 AND SEMINAL RESULTS WHICH DEMONSTRATE THAT AN EEG BASED BIOMARKER CAN PREDICT TREATMENT RESPONSE FOR INDIVIDUALS WITH PTSD OR MDD WERE PUBLISHED IN 2020 AND 2021.IN 2023, WE HAVE COMPLETED OUR ANALYSIS OF C BIOMARKER ASSAYS ON BLOOD SAMPLES COLLECTED IN THE BEST STUDY PROGRAM TO LOOK FOR GENETIC AND INFLAMMATORY MARKERS THAT MAY BE PREDICTIVE OF RESPONSE AND/OR DISEASE AND INITIATED DISSEMINATION OF THESE RESULTS AT MULTIPLE CONFERENCES.PTSD GENETICS PROGRAM:THE PSYCHIATRIC GENETICS CONSORTIUM-PTSD WORKING GROUP - BROAD INSTITUTE COLLABORATION IS SUPPORTING THE LARGEST GLOBAL GENOME WIDE ASSOCIATION STUDY ("GWAS") OF PTSD TO DATE WITH DATA FROM OVER 200,000 INDIVIDUALS ANALYZED. THE MAIN GOAL IS TO UNCOVER THE GENETIC UNDERPINNINGS OF PTSD RISK AND PUBLISH ALL RESULTS. SEMINAL FINDINGS OF THE FIRST PTSD GENETIC RISK LOCI FROM THIS PROGRAM WERE PUBLISHED IN NATURE COMMUNICATIONS IN OCTOBER 2019.IN 2022, THE GWAS PROGRAM HAS EXPANDED TO INCLUDE OVER 350,000 INDIVIDUALS WITH TRAUMA AND 2 MILLION HEALTH CONTROLS YIELDING OVER 95 IDENTIFIED GENETIC RISK LOCI.IN 2023, THE RESULTS FOR THIS ANALYSIS WERE PUBLISHED.PRISM2 (PSYCHIATRIC RATINGS USING INTERMEDIATE STRATIFIED MARKERS 2):IN 2021, WE JOINED THE INNOVATIVE MEDICINES INITIATIVE AND EUROPEAN FEDERATION OF PHARMACEUTICAL INDUSTRIES AND ASSOCIATIONS (EFPIA) AS A FUNDER AND COLLABORATOR IN THE PRISM2 STUDY PROGRAM. BUILDING ON THE SUCCESS OF INNOVATIVE RESEARCH BY THE PRISM PROJECT, THE INNOVATIVE MEDICINE INITIATIVE 2, A JOINT UNDERTAKING BETWEEN THE EU AND THE EFPIA, HAS BACKED THE PROGRAM WITH FUNDING FOR A NEW PROJECT TO EXPLORE THE UNDERLYING BIOLOGY OF ALZHEIMER'S DISEASE, SCHIZOPHRENIA AND MAJOR DEPRESSIVE DISORDER (MDD). THE NEW PRISM 2 (PSYCHIATRIC RATINGS USING INTERMEDIATE STRATIFIED MARKERS 2) PROJECT AIMS TO IDENTIFY QUANTITATIVE BIOLOGICAL FEATURES COMMON ACROSS THE DISEASES, OPENING THE POSSIBILITY OF DEVELOPING TARGETED TREATMENTS IRRESPECTIVE OF TRADITIONAL DIAGNOSIS.PRISM WAS A PAN-EUROPEAN RESEARCH PROJECT THAT RAN FROM 2016 TO 2021 AND RECEIVED $16.5 MILLION IN FUNDING FROM THE INNOVATIVE MEDICINES INITIATIVE 2 JOINT UNDERTAKING, SUPPORTED BY THE EUROPEAN UNION'S HORIZON 2020 RESEARCH AND INNOVATION PROGRAMME AND EFPIA. THE RESULTS OF PRISM CONSTITUTE THE FOUNDATION FOR THE CURRENT PRISM 2 PROJECT.THE PRISM2 PROJECT LAUNCHED IN 2022, INCLUDING PATIENT ENROLLMENT OF INDIVIDUALS WITH SCHIZOPHRENIA, DEMENTIA OR MAJOR DEPRESSION ACROSS THREE CENTERS IN EUROPE.STUDY RECRUITMENT FOR PRISM2 IS TARGETED FOR COMPLETED IN 2023.NATIONAL NORMATIVE NEUROIMAGING LIBRARY PROGRAM:CVB HAS CREATED AN IMAGING REFERENCE LIBRARY ESSENTIAL TO THE DEVELOPMENT OF EFFECTIVE CLINICAL IMAGING TOOLS FOR DIAGNOSING AND MANAGING PATIENTS WITH BRAIN DISORDERS. ADVANCED NEUROIMAGING CAN NOW DETECT MICROSCOPIC CHANGES IN BRAIN STRUCTURE CAUSED BY TRAUMA OR DISEASE. THESE ADVANCED IMAGING APPROACHES INCLUDE DIFFUSION TENSOR IMAGING ("DTI"), FUNCTIONAL CONNECTIVITY, PERFUSION WEIGHTED IMAGING, AND VOLUMETRIC IMAGING. DESPITE THEIR PROMISE, THESE ADVANCED APPROACHES ARE CURRENTLY PRIMARILY CONFINED TO RESEARCH USE. THE NUMERICAL NATURE OF THE INFORMATION THESE ADVANCED IMAGING APPROACHES YIELD IS DIFFICULT TO TRANSLATE FROM THE STUDY OF GROUPS OF INDIVIDUALS TO A SINGLE PATIENT WITHOUT A REFERENCE. THE IMAGING DATABASE IS BASED ON THE RESULTS OF A NATIONAL STUDY OF NORMATIVE INDIVIDUALS, SPONSORED BY CVB AT UNIVERSITY OF VIRGINIA, BAYLOR UNIVERSITY AND UNIVERSITY OF UTAH AND TWO MILITARY SITES. STANDARDIZED ADVANCED NEUROIMAGING SCANS ON 3,000 ADULT VOLUNTEERS, THE RESULTING IMAGING DATA, ALONG WITH DEMOGRAPHIC INFORMATION AND THE RESULTS OF NEUROCOGNITIVE ASSESSMENTS, IS FORMING A LIBRARY DOCUMENTING POPULATION VARIATION IN BRAIN STRUCTURE AND FUNCTION AS MEASURED BY THESE ADVANCED IMAGING METHODS.THROUGH THIS IMAGING DATABASE, IT IS OUR GOAL TO ADVANCE NEUROIMAGING TO DRAMATICALLY IMPROVE THE IDENTIFICATION OF AFFECTED INDIVIDUALS AND ALLOW PHYSICIANS TO OBJECTIVELY AND EFFICIENTLY DIAGNOSE CONDITIONS SUCH AS TBI, DEMENTIA AND OTHER BRAIN DISORDERS WHERE BRAIN STRUCTURE IS DETECTED VIA MRI.IN 2022, WE CONTINUED RECRUITMENT INTO THE LIBRARY, REACHING OVER 1,800 ENROLLED SUBJECTS AND ALSO ADDED BLOOD SAMPLE COLLECTION FOR NEWLY RECRUITED INDIVIDUALS. COMPUTATIONAL MODELING & DATA SCIENCES:CVB HAS ESTABLISHED AN INTRAMURAL DATA SCIENCES PROGRAM TO BUILD MACHINE-LEARNING AND ARTIFICIAL INTELLIGENCE BASED PREDICTIVE MODELS OF DISEASE. THESE PROGRAMS BUILD ON OUR ORIGINAL ORION MS BIO-MODELLING PROGRAM AND FOCUSES ON MODELS OF PTSD, TBI, PARKINSONS AND DEMENTIA AND OTHER CONDITIONS.POST-TRAUMATIC STRESS DISORDER ("PSTD") 1.0:OUR MAIN PRIORITY IS TO BUILD A MULTI-MODAL MODEL OF PTSD USING DEEPLY-PHENOTYPED COHORTS SUCH AS THE BEST STUDY AND COHEN VETERANS CENTER STUDIES. IN 2022, WE HAVE BUILT ANALYSIS PIPELINES FOR EPIGENETIC, EEG, INFLAMMATORY MARKER AND CLINICAL DATA AND WE ARE ON TRACK TO BUILD OUR FIRST MODEL BY YEAR END.PARKINSON'S PROGRESSION MARKERS INITIATIVE ("PPMI") DATA SCIENCE MODELING GROUP:EXISTING DIAGNOSES FOR COMPLEX BRAIN DISORDERS SUCH AS PARKINSON'S DISEASE FOCUS ON UNDERSTANDING CLUSTERS OF MAJOR SYMPTOMS. IN ORDER TO DRIVE PROGRESS IN THE DEVELOPMENT OF NEW TREATMENTS, IT IS IMPORTANT TO UNDERSTAND THE ROLE OF SPECIFIC BIOLOGICAL PROCESSES IN DETERMINING PATIENT OUTCOMES. IN THIS PROGRAM, WE MODEL THE MICHAEL J. FOX FOUNDATION ("MJFF") SPONSORED PARKINSON'S PROGRESSION MODEL INITIATIVE STUDY. THE STUDY HAS EVALUATED PARTICIPANTS' CLINICAL STATUS WHILE COLLECTING IMAGING, BEHAVIORAL, 'OMICS AND OTHER ASSESSMENTS LONGITUDINALLY SINCE 2010. IN OUR ALIGNED MISSIONS TO ADVANCE BRAIN HEALTH, MJFF SELECTED CVB'S DATA SCIENCE TEAM TO LEVERAGE THIS COHORT TOGETHER WITH A MULTI-DISCIPLINARY APPROACH TO QUANTITATIVELY EXPLORE, EVALUATE, AND PREDICT DISEASE TRAJECTORY, RISK FACTORS, AND SUBTYPES. GIVEN THE BREADTH AND DEPTH OF THE PPMI DATA AND RICH OPPORTUNITIES TO DEVELOP IMPACTFUL DISEASE MODELS, THE TEAM USE THEIR SUBJECT MATTER EXPERTISE ACROSS TRANSLATIONAL SCIENCE TO GENERATE INSIGHTS FROM 'OMICS, IMAGING, GENETIC AND CLINICAL DATA BY INTEGRATING TECHNIQUES ACROSS ADVANCED STATISTICS, MACHINE LEARNING, AND COMPUTATIONAL MODELING TO FACILITATE PD BIOMARKER DISCOVERY AND DEEPEN OUR UNDERSTANDING OF DISEASE PROGRESSION.MULTIPLE SCLEROSIS ("MS") 1.0:THE ORION BIONETWORKS FLAGSHIP PROGRAM SUCCESSFULLY PILOTED THE ESTABLISHMENT OF A MULTIPLE SCLEROSIS BIONETWORK COMPRISED OF ACADEMIC (NEUROSCIENCE INSTITUTE OF THE BRIGHAM AND WOMEN'S HOSPITAL), ADVOCACY (ACCELERATED CURE PROJECT FOR MS), COMPUTATIONAL (GNS HEALTHCARE, METACELL, THOMSON REUTERS), INFORMATICS (CONVERGE BY DELOITTE, RANCHO BIOSCIENCES, EXAPTIVE), AND ONLINE PATIENT COMMUNITY PARTNERS (PATIENTSLIKEME [PLM]). DE-IDENTIFIED HIPPA-COMPLIANT DATA FROM THREE DATABASES WERE CURATED AND LOADED INTO A CLOUD-BASED DATA KNOWLEDGE MANAGEMENT SYSTEM. THE INTEGRATED REPOSITORY INCLUDES 9,000 SUBJECTS WITH MS AND RELATED CONDITIONS. THE ALLIANCE DEVELOPED A ROADMAP FOR JOINT EXECUTION WITH SPECIFIC SCIENTIFIC AIMS. THE ALLIANCE HAS GENERATED MULTIPLE MODELS BASED ON THE DATA REPOSITORY USING DIFFERENT ALGORITHMIC APPROACHES: PHENOTYPIC PROGNOSTIC MODEL AND TWO MOLECULAR PROGNOSTIC MODELS.PTSD AND TBI PRECLINICAL MODELING PROGRAM:ANIMAL MODELS OF PSYCHIATRIC DISORDERS OFFER A COMPLEMENTARY RESEARCH MODALITY THAT SUPPORTS CLINICAL RESEARCH. IN ORDER TO ACHIEVE A SATISFACTORY DEGREE OF VALIDITY AND RELIABILITY, ANIMAL MODELS OF COMPLEX AND INTRICATE PSYCHIATRIC DISORDERS, SUCH AS PTSD, MUST FULFILL CERTAIN CRITERIA: PATHOGENIC PROCESSES MUST BE OBSERVABLE AND MEASURABLE, AND MUST RELIABLY REFLECT CLINICAL SYMPTOMATOLOGY, AND PHARMACOLOGICAL AGENTS THAT ARE KNOWN TO AFFECT SYMPTOMS IN HUMAN SUBJECTS, SHOULD MODULATE THESE PROCESSES. CVB HAS ESTABLISHED THE ALLIANCE FOR MODELS OF PTSD, INNOVATIVE TECHNOLOGIES AND UNIFORM PRACTICES ("AMP-IT- UP") TO SUPPORT PRECLINICAL MODEL DEVELOPMENT. MULTIPLE SUB-GRANT AWARDS COMPLETED AND PUBLISHED THEIR FINDING THIS YEAR IN SUPPORT THE MISSION OF THIS PROGRAM.PEERS - THE PLATFORM FOR THE EXCHANGE OF EXPERIMENTAL RESEARCH STANDARDS:PEERS IS A PLATFORM THAT ENABLES SHARING OF INFORMATION ON PARAMETERS THAT AFFECT THE ROBUSTNESS OF PRECLINICAL DATA. PEERS IS LIKE A WIKI ON HOW TO DESIGN, CONDUCT AND ANALYZE EXPERIMENTS TO INCREASE DATA ROBUSTNESS. PEERS ALLOWS USERS TO SEARCH FOR FACTORS AND PARAMETERS THAT ARE OF RELEVANCE TO THEIR EXPERIMENTS AND GIVES GUIDANCE AND ADVICE ON HOW TO LEVERAGE THESE FACTORS TO INCREASE THE QUALITY, ROBUSTNESS AND REPRODUCIBILITY OF RESEARCH. PEERS ALLOWS USERS TO: (1) SEARCH FOR FACTORS AND PARAMETERS THAT ARE OF RELEVANCE TO THEIR EXPERIMENTS (2) FIND RECOMMENDATIONS AND BEST PRACTICES ON EXPERIMENTAL DESIGN, EXECUTION AND DATA ANALYSIS FOR SPECIFIC IN VITRO METHODS OR IN VIVO MODELS (3) SHARE EXPERIENCES AND KNOWLEDGE TO HELP OTHERS BUILD HIGH-QUALITY, REPRODUCIBLE DATA SETS (4) CITE CONTRIBUTIONS (5) INCREASE THE QUALITY, ROBUSTNESS AND REPRODUCIBILITY OF RESEARCH.ADDRESSING SEX AS A BIOLOGICAL VARIABLE IN PRECLINICAL RESEARCH:DIFFERENCES BETWEEN MALES AND FEMALES EXTEND WELL BEYOND REPRODUCTION, WITH SIGNIFICANT IMPLICATIONS FOR HUMAN HEALTH AND DISEASE. THIS IS PARTICULARLY THE CASE IN THE FIELD OF NEUROSCIENCE, WHERE DIFFERENCES IN BASIC BIOLOGY BETWEEN MEN AND WOMEN CAN LEAD TO SEX DIFFERENCES IN THE PREVALENCE, PROGRESSION, AND RESPONSES TO TREATMENT OF MANY BRAIN DISORDERS.THIS VIDEO TRAINING SERIES WAS DEVELOPED AND LAUNCHED BY COHEN VETERANS BIOSCIENCE IN 2022, TO ENSURE THAT EARLY-STAGE RESEARCH IS CONDUCTED TO THE HIGHEST AND MOST RIGOROUS STANDARDS POSSIBLE. ONE SOLUTION IS TO ENSURE THAT THE RESEARCH COMMUNITY - INCLUDING GRADUATE STUDENTS, POSTDOCS, AND OTHER EARLY CAREER RESEARCHERS - HAVE THE TOOLS THEY NEED TO ENABLE THE IMPLEMENTATION OF BEST PRACTICES ACROSS THE EXPERIMENTAL PROCESS. THE GOAL OF THE VIDEO TRAINING SERIES, WHICH CONTAINS THREE MODULES, WAS TO PROVIDE PRACTICAL GUIDANCE TO PRECLINICAL RESEARCHERS ON HOW TO NAVIGATE THE NIH'S 2015 POLICY ON INCORPORATING SEX AS A BIOLOGICAL VARIABLE INTO THEIR CURRENT AND FUTURE RESEARCH.GLOBAL PRECLINICAL DATA FORUM:THE GLOBAL PRECLINICAL DATA FORUM ("GPDF") IS A JOINTLY SPONSORED U.S. AND EUROPEAN INITIATIVE THAT ENCOURAGES GLOBAL COLLABORATION TO ADDRESS THE CHALLENGE OF ENSURING THAT PRECLINICAL RESEARCH IS REPRODUCIBLE, ROBUST AND TRANSLATABLE TO SUPPORT DISEASE RESEARCH UTILITY FOR CLINICAL RESEARCH & DEVELOPMENT ("R&D"). IT SUPPORTS BEST RESEARCH PRACTICES, THE DEVELOPMENT AND IMPLEMENTATION OF DATA QUALITY STANDARDS, PRECLINICAL DATA & TECHNOLOGICAL PLATFORMS, AND TRAINING PROGRAMS FOR THE NEUROSCIENCE COMMUNITY WITH THE GOAL OF ENHANCING THE DATA UTILITY DERIVED FROM PRECLINICAL MODELS.THIS IS OUR FIFTH YEAR SUPPORTING, WITH THE EUROPEAN COLLEGE OF NEUROPHARMACOLOGY ("ECNP"), THE WORLD'S FIRST NEGATIVE DATA PRIZE AS AN INCENTIVE FOR PRECLINICAL RESEARCHERS TO PUBLISH "NEGATIVE DATA" RESULTS TO ENSURE ALL NEUROSCIENCE STUDIES PROPERLY ADVANCE KNOWLEDGE. THE PRIZE IS AWARDED TO THE RESEARCHER OR RESEARCH GROUP WHOSE NEUROSCIENCE STUDY BEST EXEMPLIFIES DATA WHERE THE OUTCOMES DO NOT CONFIRM THE EXPECTED RESULTS OR WORKING HYPOTHESIS. THE PRECLINICAL AWARD WAS PRESENTED DURING THE 2020 VIRTUAL ECNP CONFERENCE.IN 2023 WE CONTINUED TO AWARD THE BEST NEGATIVE PRIZE AWARDS PROGRAM TO CLINICAL RESEARCHERS WHOSE NEUROSCIENCE STUDY BEST EXEMPLIFIES DATA WHERE THE OUTCOMES DO NOT CONFIRM THE EXPECTED RESULTS OR WORKING HYPOTHESIS.EQIPD QUALITY SYSTEM:THE GPDF AND COHEN VETERANS BIOSCIENCE ARE BOTH MAJOR CONTRIBUTORS TO THE EUROPEAN UNION INNOVATIVE MEDICINE INITIATIVE-FUNDED CONSORTIUM CALLED EQIPD (EQIPD.ORG). THE EQIPD CONSORTIUM HAS DEVELOPED A NOVEL PRECLINICAL RESEARCH QUALITY SYSTEM THAT CAN BE APPLIED IN BOTH PUBLIC AND PRIVATE SECTORS AND IS FREE FOR ANYONE TO USE. THE EQIPD QUALITY SYSTEM WAS DESIGNED TO BE SUITED TO BOOST INNOVATION BY ENSURING THE GENERATION OF ROBUST AND RELIABLE PRECLINICAL DATA WHILE BEING LEAN, EFFECTIVE AND NOT BECOMING A BURDEN THAT COULD NEGATIVELY IMPACT THE FREEDOM TO EXPLORE SCIENTIFIC QUESTIONS. EQIPD DEFINES RESEARCH QUALITY AS THE EXTENT TO WHICH RESEARCH DATA ARE FIT FOR THEIR INTENDED USE. FITNESS, IN THIS CONTEXT, IS DEFINED BY THE STAKEHOLDERS, WHO ARE THE SCIENTISTS DIRECTLY INVOLVED IN THE RESEARCH, BUT ALSO THEIR FUNDERS, SPONSORS, PUBLISHERS, RESEARCH TOOL MANUFACTURERS AND COLLABORATION PARTNERS SUCH AS PEERS IN A MULTI-SITE RESEARCH PROJECT. THE ESSENCE OF THE EQIPD QUALITY SYSTEM IS THE SET OF 18 CORE REQUIREMENTS THAT CAN BE ADDRESSED FLEXIBLY, ACCORDING TO USER-SPECIFIC NEEDS AND FOLLOWING A USER-DEFINED TRAJECTORY. THE EQIPD QUALITY SYSTEM PROPOSES GUIDANCE ON EXPECTATIONS FOR QUALITY-RELATED MEASURES, DEFINES CRITERIA FOR ADEQUATE PROCESSES (I.E., PERFORMANCE STANDARDS) AND PROVIDES EXAMPLES OF HOW SUCH MEASURES CAN BE DEVELOPED AND IMPLEMENTED. IN 2023, EQIPD WAS AWARDED A MAJOR GRANT (ISTAND) BY THE INNOVATIVE MEDICINES INITIATIVE IN EUROPE. THERE IS CURRENTLY NO ESTABLISHED FRAMEWORK READILY AVAILABLE OUTSIDE OF SELECTED COMPANIES AND RESEARCH ORGANIZATIONS THAT APPLY INTERNALLY-DEVELOPED STANDARDS AND CRITERIA TO SUPPORT ADEQUATE RESEARCH RIGOR THAT IS COMMENSURATE WITH THE PURPOSE AND APPROPRIATELY ACHIEVABLE. THE GRANT PROGRAM WILL ESTABLISH AND TEST SUCH A FRAMEWORK TO SUPPORT THE PROCESSES OF GENERATING AND REPORTING NONREGULATED RESEARCH RESULTS, AND TO SYSTEMATIZE DECISION-MAKING BASED ON SUCH RESULTS. IT COULD BE APPLIED TO NONREGULATED RESEARCH IN ANY DOMAIN (I.E., RESEARCH NOT CONDUCTED UNDER GOOD PRACTICE GXP STANDARDS SUCH AS GLP), INCLUDING THE DEVELOPMENT OF BIOMARKERS.POLICY & ADVOCACY INITIATIVES:WE ARE COMMITTED TO ADVOCATING FOR POLICY REFORMS AT THE FEDERAL LEVEL THAT BUILD UPON EVIDENCE-BASED PRECISION MEDICINE APPROACHES AND HAVE THE POWER TO BRING NEW SOLUTIONS FOR PTSD AND TBI IN YEARS, NOT DECADES. AS PART OF OUR ADVOCACY EFFORTS, WE CO-FOUNDED THE COALITION TO HEAL INVISIBLE WOUNDS (THE "COALITION"), A COLLABORATIVE INITIATIVE AIMED AT ADVOCATING FOR POLICY REFORMS TO WIDEN AND EXPEDITE THE PIPELINE FOR NEW THERAPIES AND DIAGNOSTICS FOR PTSD AND TBI - WHICH CAN BOTH DRASTICALLY INCREASE THE RISK OF SUICIDE AMONG VETERANS. IN 2023, WE CONTINUE TO GROW MEMBERSHIP IN THE ALLIANCE AS WELL AS CONTRIBUTE TO THE ADVANCEMENT OF SEMINAL LEGISLATION TO SUPPORT VETERANS AND BRAIN RESEARCH. 11846371 1 1 0 1 0 0 0 0 0 0 1 0 0 1 1 0 0 0 0 1 0 0 0 0 0 0 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 1 26 0 29 1 0 0 0 0 0 0 0 0 0 0 0 0 X 5 4 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 MA NY AL AR CA DC FL GA HI IL KS KY MD MI MN MS NH NJ NC OR PA RI SC TN UT VA WV WI X X GELMAN ROSENBERG AND FREEDMAN CPA 3019519090 4550 MONTGOMERY AVENUE SUITE 650N BETHESDA MD 20814 MAGALI HAAS MD PHD FORMER CEO 60.00 X X 497238 0 14911 ALLYSON GAGE PHD FORMER CHIEF MEDICAL OFFICER 40.00 X 396239 0 29985 LEE LANCASHIRE FORMER CHIEF INFORMATION OFFICER 40.00 X 330795 0 71270 PETER HOEHN FORMER CHIEF EXECUTIVE OFFICER 40.00 X 345622 0 42061 NICOLE HARMON FORMER PRESIDENT 40.00 X 293027 0 46040 EVGENY RAKHMATULIN FORMER CHIEF TECHNOLOGY OFFICER 40.00 X 250919 0 48801 RAGINI VERMA FORMER HEAD OF BIOMAKERS & CLINICAL DEV. 40.00 X 256653 0 25526 MARYAN ZIRKLE FORMER EXECUTIVE DIRECTOR, BRAINCOMMONS 40.00 X 245635 0 26527 LAUREN GOLDSMITH FORMER SENIOR DIRECTOR, CONTRACTS & GRANT MGMT 40.00 X 238242 0 25626 MARK ZERVAS FORMER HEAD OF DISCOVERY AND PRECLINICAL RESEARCH 40.00 X 206998 0 45806 MICHAEL CARSON FORMER HEAD OF COMMUNICATIONS 40.00 X 211087 0 21937 MICHAEL SULLIVAN BOARD TREASURER 1.00 X X 0 0 0 THERESA FRANGIOSA FORMER BOARD SECRETARY 1.00 X X 0 0 0 DAVE DEMARCO BOARD MEMBER 1.00 X 0 0 0 DAVID BIONDI BOARD MEMBER 1.00 X 0 0 0 FRANK LARKIN BOARD MEMBER 1.00 X 0 0 0 3272455 0 398490 21 0 1 0 DISCOVERY LIFE SCIENCES 800 HUDSON WAY SUITE 1700 HUNTSVILLE AL 35806 SAMPLE EXTRACTION AND REPORTING 437879 CLARIVATE ANALYTICS (US) LLC 1500 SPRING GARDEN 4TH FLOOR PHILADELPHIA PA 19130 TECHNOLOGY CONSULTING AND DATA CURATION 393912 GRF CPA'S & ADVISORS 4550 MONTGOMERY AVENUE SUITE 800 N BETHESDA MD 20814 ACCOUNTING SERVICES 392943 MORGAN LEWIS & BOCKIUS LLP 1701 MARKET STREET PHILADELPHIA PA 19103 LAW SERVICES FOR VARIOUS PROJECTS 308496 TONE CREATIVE LLC 63 PUTNAM STREET SUITE 202 SARASOTA SPRINGS NY 12866 MARKETING AND DESIGN SERVICES 271230 11 8131591 8131591 51935 51935 GRANT REFUNDS 900099 139544 139544 OTHER REFUNDS 900099 53200 53200 OTHER INCOME 900099 1481 1481 194225 8377751 194225 0 51935 X 31373 31373 2984375 2656094 208906 119375 4395469 3917302 324185 153982 149453 133168 11028 5257 249196 222065 18475 8656 329016 293039 23816 12161 466905 332906 133999 491490 491490 60000 60000 2331567 2040144 272128 19295 426380 221813 199333 5234 587614 505663 81024 927 456098 395769 60309 20 300223 262597 36529 1097 115988 114809 1179 625625 621148 2964 1513 79138 38481 39060 1597 14079910 11846371 1904425 329114 828606 402891 5471810 1247450 1762522 52 98344 65574 2508484 2339535 1967457 168949 1614659 1190359 11743398 3075275 1818611 2172902 740285 0 1294809 932942 3853705 3105844 X 5480842 -30569 2408851 0 7889693 -30569 11743398 3075275 X -5702159 -2218103 X X 0 0 0 X 16316026 16160581 17941055 9750042 8131591 68299295 16316026 16160581 17941055 9750042 8131591 68299295 62141279 6158016 154639 59585 28608 223966 51935 518733 32104 112735 364187 194225 703251 69521279 0.08860 0.10250 X COHEN VETERANS BIOSCIENCE, INC. ("CVB") IS A PUBLIC CHARITY BIOMEDICAL RESEARCH AND TECHNOLOGY ORGANIZATION DEDICATED TO ADVANCING BRAIN HEALTH BY FAST-TRACKING PRECISION DIAGNOSTICS AND TAILORED THERAPEUTICS. WE ARE LEADING THE WAY TO CURE INVISIBLE WOUNDS FOR THE MILLIONS OF VETERANS, SERVICE MEMBERS, FIRST RESPONDERS, AND CIVILIANS WHO SUFFER FROM TRAUMA-RELATED CONDITIONS, SUCH AS PTSD, TBI AND SUICIDE. CVB IS CATALYZING RESEARCH TO ADVANCE BRAIN HEALTH AT ALL STAGES FROM SCIENTIFIC DISCOVERY TO CLINICAL APPLICATION.THIS MEMO PROVIDES EVIDENCE OF QUANTITATIVE AND QUALITATIVE MEASURES WHICH SUPPORT CVB'S PURSUIT OF PUBLIC CHARITY STATUS. CVB MET THE QUANTITATIVE PERCENTAGE TEST CRITERION FOR SUPPORTING FACTS AND CIRCUMSTANCES IN FY23. IN FY24, WE DIPPED UNDER THE 10% THRESHOLD DUE TO COMBINED EXTERNAL FACTORS.CVB ENGAGES WITH AND MAKES AVAILABLE TO RESEARCHERS, POLICY MAKERS, AND THE GENERAL PUBLIC A BROAD ARRAY OF PROGRAMS, TOOLS, SERVICES, AND INFORMATION WHICH ADVANCE THE STATE OF BRAIN SCIENCE, GUIDED BY AN INDEPENDENT BOARD AND ADVISORY COUNCILS IN CONJUNCTION WITH CVB'S RENOWNED EXPERTS IN RELEVANT FIELDS OF NEUROSCIENCE, DATA SCIENCE AND PHARMACEUTICAL RESEARCH AND DEVELOPMENT. FOLLOWING ARE MORE DETAILED EVIDENCE OF THESE FACTS AND CIRCUMSTANCES. COHEN VETERANS BIOSCIENCE, INC. EARLY ORIGINS WERE AS AN ORGANIZATION UNDER THE FISCAL SPONSORSHIP OF THE MARIN COUNTY COMMUNITY FOUNDATION, LATER ESTABLISHED AS A STAND-ALONE 501(C)3 IN 2014 UNDER THE NAME ORION BIONETWORKS. CVB'S FOUNDER AND CEO HAS A PERSONAL CONNECTION TO THE PUBLIC WORK THE ORGANIZATION CARRIES OUT BY VIRTUE OF HER HUSBAND BEING A VETERAN OF THE US AIRFORCE SERVICE AND HER SISTER SERVING AS AN AIRFORCE COLONEL, WITH ACTIVE DEPLOYMENTS TO OEF/OIF. THE FORMAL NAME CHANGE TO COHEN VETERANS BIOSCIENCE TOOK PLACE IN 2015 IN CONCERT WITH GENEROUS SEED FUNDING FROM STEVEN A. COHEN. CVB QUALIFIES AS A PUBLIC CHARITY UNDER THE "FACTS AND CIRCUMSTANCES" TEST OF 1.170A-9(F)(3) OF THE TREASURY REGULATIONS, BASED UPON THE FOLLOWING:CVB IS ORGANIZED AND OPERATED SO AS TO ATTRACT NEW AND ADDITIONAL FUNDING ON A CONTINUOUS AND BONA FIDE BASIS; CVB'S CURRENT FUNDRAISING PLANS ARE TARGETED AT A BROAD BASE OF DONORS, INCLUDING FOUNDATIONS, INDIVIDUALS, AND GOVERNMENT AGENCIES. ONLINE GIVING: CVB HAS HAD A DONATION BUTTON ON ITS WEBSITE AND ALL SOCIAL MEDIA SINCE INCEPTION. AS OF FY22, WE ESTABLISHED REGISTERED STATUS ACROSS ALL 50 STATES. THE ORGANIZATION RUNS SEVERAL ONLINE DONATION CAMPAIGNS THROUGHOUT THE YEAR (E.G. MEMORIAL DAY, VETERANS DAY, GIVING DAY). IN FY24, THE ORGANIZATION APPLIED FOR AND RECEIVED APPROVAL TO PARTICIPATE IN THE U.S. GOVERNMENT'S COMBINED FEDERAL CAMPAIGN FOR CHARITABLE ORGANIZATIONS.FUNDRAISING EVENTS: WE CONTINUE TO GROW OUR REACH TO THE GENERAL PUBLIC THROUGH FUNDRAISING EVENTS, SOME SPONSORED DIRECTLY AND OTHERS ON OUR BEHALF THROUGH OUR AMBASSADOR'S PROGRAM AND ALSO A CROWDRISE CAMPAIGN CAPABILITY WE ADDED TO OUR WEBSITE IN FY23. STARTING IN 2020, WE ENGAGED IN PARTNERSHIPS WITH VETERANS SERVICE ORGANIZATIONS WHO HAVE COMMITTED TO RAISE AWARENESS OF INDIVIDUALLY DRIVEN FUNDRAISING CAMPAIGNS FOR VETERANS PTSD, TBI AND SUICIDE. MEMBERSHIP PROGRAMS:- IN 2022, WE LAUNCHED AN ANNUAL MEMBERSHIP PROGRAM WITH OTHER NONPROFIT FOUNDATIONS, UNDER OUR COALITION TO HEAL INVISIBLE WOUNDS, TO SUPPORT ADVOCACY AND EDUCATION INITIATIVES.- IN 2023, WE EXPANDED OUR TBI ACTION ALLIANCE PROGRAM WHICH INCLUDES BOTH MEMBERSHIP AND SPONSORSHIP OPPORTUNITIES FOR INDIVIDUALS, PROFESSIONALS, AND INSTITUTIONS TO SUPPORT OUR RESEARCH PROGRAMS TO ADVANCE DIAGNOSTICS AND THERAPEUTICS FOR TRAUMATIC BRAIN INJURIES (TBI). WE HAVE OVER 50 MEMBERS AND INSTITUTIONS ENROLLED TO DATE.GOVERNMENT & FOUNDATION RESEARCH GRANTS: IN EARLY FY24, CVB RECEIVED NEW GRANT SUPPORT FROM THE US NATIONAL INSTITUTES OF HEALTH AND THE DEPARTMENT OF DEFENSE AS WELL AS GRANTS FROM THE GATES FOUNDATION, BRAINMIND FOUNDATION AND INTERNATIONAL FOUNDATIONS INTERESTED IN SUPPORTING OUR RESEARCH PROGRAMS ACROSS PTSD, TBI AND BRAIN HEALTH;AS EVIDENCED BY THE EXTENSIVE PROGRAMS SPONSORED BY CVB SUPPORTING RESEARCH COLLABORATIONS AND SCIENTIFIC BEST PRACTICE ADOPTION, CVB REMAINS AN ORGANIZATION COMMITTED TO SERVING THE PUBLIC THROUGH ITS WORK. EXAMPLES WHICH DEMONSTRATE OUR COMMITMENT TO THE PUBLIC BENEFIT AND PUBLIC PARTICIPATION IN OUR EFFORTS INCLUDE CVB'S VETERANS ADVISORY COUNCIL, STATE OF THE SCIENCE SUMMITS, NUMEROUS EXPERT WORKSHOPS, ENSURING OUR RESEARCH IS PUBLISHED IN OPEN ACCESS PUBLICATIONS, AND DATA SHARING POLICIES ENCOURAGING RESEARCH COLLABORATION ACROSS ORGANIZATIONAL BOUNDARIES. CVB PROGRAM ACTIVITIES, WITH TEAM SCIENCE AND COLLABORATION AS A CORE BELIEF, PROVIDES DIRECT PUBLIC BENEFIT THROUGH ITS RESEARCH AND EDUCATIONAL ACTIVITIES. CVB SPEARHEADS RESEARCH WITH MULTI-SECTOR PARTNERS INCLUDING ACADEMIA, GOVERNMENT, FOUNDATION RESEARCH, AND INDUSTRY ORGANIZATIONS TO ADVANCE COLLECTIVE UNDERSTANDING OF AND APPROACHES TO IMPROVING BRAIN HEALTH. FOR EXAMPLE, CVB SPONSORED THE BRAIN TRAUMA BLUEPRINT IN PARTNERSHIP WITH THE VETERANS ADMINISTRATION, NATIONAL INSTITUTES OF HEALTH AND DEPARTMENT OF DEFENSE TO ESTABLISH A RESEARCH ROADMAP FOR THE ADVANCEMENT OF PRECISION THERAPEUTIC SOLUTIONS FOR TRAUMATIC BRAIN INJURY (HTTPS://WWW.BRAINTRAUMABLUEPRINT.ORG/). CVB ALSO BROADLY DISSEMINATES RESEARCH AND EDUCATIONAL INFORMATION ABOUT PTSD, TRAUMATIC BRAIN INJURY (TBI) AND SUICIDE DIRECTLY TO THE PUBLIC THROUGH ITS WEBSITE AND SOCIAL MEDIA. THE INFORMATION IS PROVIDED IN AN ACCESSIBLE AND UNDERSTANDABLE FORMAT FOR ANY NON-MEDICAL READER, HELPING VETERANS AND OTHERS SUFFERING FROM PTSD OR TBI TO UNDERSTAND THEIR CONDITIONS AND THE SYMPTOMS AND CAUSES ASSOCIATED WITH THEM. THESE MATERIALS ALSO SERVE TO EDUCATE THE PUBLIC ABOUT PTSD AND TBI AND THE EFFECTS OF THESE CONDITIONS ON OUR VETERANS AND FAMILIES. THESE EVENTS, PROCEEDINGS, AND OTHER EDUCATIONAL OUTREACH SERVE TO ADVANCE BRAIN SCIENCE IN THE PUBLIC INTEREST. SEE WWW.COHENVETERANSBIOSCIENCE.ORG AND THE FORM 990 PROGRAM DESCRIPTIONS FOR MORE DETAILS ON THE EXPANSIVE NATURE OF THESE PROGRAMS. CVB ALSO ENLISTS THE ACTIVE SUPPORT AND PARTICIPATION OF EXPERTS, PUBLIC OFFICIALS, AND COMMUNITY LEADERS. CVB'S VETERANS ADVISORY COUNCIL ("VAC") INCLUDES SENIOR LEADERS WHO SERVED IN MILITARY LEADERSHIP ROLES AND/OR HAVE VETERAN FAMILY MEMBERS AND HAVE A DEEP PERSONAL COMMITMENT TO VETERANS' CONCERNS RELATED TO BRAIN HEALTH. VAC HELPS REPRESENT, ADVOCATE AND SUPPORT MILITARY AND VETERANS' INTERESTS TO CVB TO AID CVB IN DELIVERING MEANINGFUL RESULTS FOR VETERANS THROUGH DATA-DRIVEN SCIENCE AND ADVOCACY. MORE INFORMATION ABOUT VAC IS AVAILABLE HERE: HTTPS://WWW.COHENVETERANSBIOSCIENCE.ORG/VETERANS-ADVISORY-COUNCIL/ IN 2020, CVB EXPANDED ITS GLOBAL FOOTPRINT BY FORGING A PARTNERSHIP WITH THE EUROPEAN COLLEGE OF NEUROPSYCHOPHARMACOLOGY TO ESTABLISH THE GLOBAL PRECLINICAL DATA FORUM, IN SUPPORT OF REPRODUCIBLE RESEARCH EFFORTS (HTTPS://WWW.PRECLINICALDATAFORUM.ORG/). CVB ALSO JOINED THE EUROPEAN FEDERATION OF PHARMACEUTICAL INDUSTRIES AND ASSOCIATIONS TO CO-SPONSOR RESEARCH WITH THE INNOVATIVE MEDICINES INITIATIVE (HTTPS://WWW.IMI.EUROPA.EU/PROJECTS-RESULTS/PROJECT-FACTSHEETS/PRISM-2) AT AN INTERNATIONAL LEVEL, AND WAS PART OF A GRANT AWARD, PRISM2, THAT COMPLETED IN 2024. IN FY24, WE RECEIVED MAJOR FUNDING FROM THE CANADIAN ONTARIO BRAIN INSTITUTE IN SUPPORT OF OUR BRAIN HEALTH INITIATIVES.FINALLY, CVB HAS A REPRESENTATIVE GOVERNING BODY THROUGH ITS UNCOMPENSATED BOARD OF DIRECTORS CONSISTING OF FIVE MEMBERS WITH EQUAL VOTING RIGHTS. FOUR OF THE FIVE MEMBERS ARE INDEPENDENT OF THE LARGEST DONOR. ALL OF THE BOARD MEMBERS ARE INDIVIDUALS WITH SPECIAL KNOWLEDGE AND EXPERTISE RELEVANT TO THE ORGANIZATION'S CHARITABLE ACTIVITIES IN BRAIN SCIENCE AND HEALTH, AS WELL AS MEMBERS WITH LONGSTANDING DEDICATION TO THE NEEDS OF VETERANS AND OTHERS WHO SUFFER FROM BRAIN DISEASES THROUGH BOTH PAID AND UNPAID WORK WITH GOVERNMENT AND OTHER NONPROFIT AGENCIES. THE QUALIFICATIONS OF THE BOARD MEMBERS INCLUDE:BOARD CHAIR AND CEO, MAGALI HAAS, MD, PHD FOUNDED ORION BIONETWORKS (RENAMED TO COHEN VETERANS BIOSCIENCE IN 2015) WITH SPONSORSHIP FROM JANSSEN RESEARCH & DEVELOPMENT TO UNLOCK THE POWER OF SHARED DATA AND PREDICTIVE MODELING TO HELP TRANSFORM OUR UNDERSTANDING OF BRAIN DISEASES AND ACCELERATE THE SEARCH FOR CURES.DR. HAAS HAS OVER 20 YEARS OF PHARMACEUTICAL EXECUTIVE AND CLINICAL RESEARCH EXPERIENCE INCLUDING DEVELOPMENT LEADERSHIP ROLES IN MEDICAL MARKETING, FULL CLINICAL DEVELOPMENT, EARLY DEVELOPMENT, AND TRANSLATIONAL AND BIOMARKER SCIENCES IN PSYCHIATRY AND NEUROLOGY. SHE LED DEVELOPMENT TEAMS EVALUATING COMPOUNDS FOR SCHIZOPHRENIA, BIPOLAR DISORDER, DEPRESSION, NEUROPATHIC PAIN, EPILEPSY, AND MIGRAINE DISORDER.SHE SERVED 3 YEARS AS CHIEF SCIENCE AND TECHNOLOGY OFFICER FOR ONE MIND FOR RESEARCH, A NONPROFIT ORGANIZATION LAUNCHED IN MAY 2012 BY PATRICK J KENNEDY. SCHEDULE A, PART II, LINE 10, EXPLANATION OF OTHER INCOME: HRA FORFEITURES - 2020 AMOUNT: $ 28,475. STIMULUS/COVID CREDITS - 2020 AMOUNT: $ 3,629. 2021 AMOUNT: $ 2,480. OTHER REFUNDS - 2021 AMOUNT: $ 110,255. 2023 AMOUNT: $ 53,200. OTHER INCOME - 2022 AMOUNT: $ 37,205. 2023 AMOUNT: $ 1,481. GRANT REFUNDS - 2022 AMOUNT: $ 326,982. 2023 AMOUNT: $ 139,544. PART II SECT C LINE 17A FACTS & CIRCUMSTANCES TEST (CONT): DR. HAAS EARNED HER BS IN BIOENGINEERING FROM THE UNIVERSITY OF PENNSYLVANIA, AN MS IN BIOMEDICAL ENGINEERING FROM RUTGERS UNIVERSITY, NEW JERSEY, AND HER MD PHD WITH DISTINCTION IN NEUROSCIENCE FROM ALBERT EINSTEIN COLLEGE OF MEDICINE, NEW YORK. VICE-CHAIR, BOARD MEMBER, FRANK LARKIN WAS FORMERLY THE UNITED STATES SENATE SERGEANT AT ARMS (SAA). AS CHIEF LAW ENFORCEMENT AND EXECUTIVE OFFICER OF THE SENATE, THE SAA ENFORCES RULES OF THE SENATE; PROVIDES A RANGE OF TECHNICAL AND ADMINISTRATIVE SERVICES TO SENATORS IN THEIR WASHINGTON, DC, AND STATE OFFICES; AND MAINTAINS SECURITY IN THE CAPITOL AND SENATE OFFICE BUILDINGS. FRANK WAS A MEMBER OF THE SENIOR EXECUTIVE SERVICE, RECENTLY SERVING AS BOTH THE ACTING DIRECTOR AND THE VICE DIRECTOR OF THE JOINT IMPROVISED EXPLOSIVE DEVICE DEFEAT ORGANIZATION (JIEDDO) WITHIN THE DEPARTMENT OF DEFENSE. HE PREVIOUSLY SERVED AS JIEDDO'S DIRECTOR FOR THE COUNTER IED OPERATIONS-INTELLIGENCE INTEGRATION CENTER. JIEDDO'S MISSION WAS TO FOCUS ALL DEPARTMENT OF DEFENSE ACTIONS IN SUPPORT OF THE COMBATANT COMMANDERS' EFFORTS TO DEFEAT IMPROVISED EXPLOSIVE DEVICES (IEDS) AS WEAPONS OF STRATEGIC INFLUENCE. FRANK'S FOCUS WAS IN SUPPORT OF OUR DEPLOYED WARFIGHTERS AND SPECIAL OPERATIONS FORCES AROUND THE GLOBE AND THE INTEGRATION OF A "WHOLE OF GOVERNMENT" DISRUPTION EFFORT TARGETING EXTREMIST NETWORKS THAT EMPLOY IEDS. FRANK SERVED FOR MORE THAN TWO DECADES IN THE UNITED STATES SECRET SERVICE (USSS), BEGINNING IN 1984 AS A SPECIAL AGENT ASSIGNED TO THE PHILADELPHIA AND WASHINGTON FIELD OFFICES, BEFORE ASSIGNMENT TO THE PRESIDENTIAL PROTECTIVE DIVISION. HE WAS ASSIGNED TO THE OFFICE OF CONGRESSIONAL AFFAIRS FOR A TWO-YEAR FELLOWSHIP ON CAPITOL HILL, SERVING A YEAR EACH WITH THE SENATE AND HOUSE APPROPRIATIONS COMMITTEES. FRANK ENTERED THE USSS SUPERVISORY RANKS AS ASSISTANT TO THE SPECIAL AGENT IN CHARGE OF THE NEW YORK FIELD OFFICE, WHERE HE LED FINANCIAL, ELECTRONIC, AND ORGANIZED CRIMES INVESTIGATIONS. FOLLOWING THE EVENTS OF 9/11, HE RETURNED TO WASHINGTON, DC, AS THE ASSISTANT SPECIAL AGENT IN CHARGE OF THE PRESIDENTIAL PROTECTIVE DIVISION, SUPERVISING WHITE HOUSE SECURITY OPERATIONS. AS ASSISTANT SPECIAL AGENT IN CHARGE OF THE TECHNICAL SECURITY DIVISION, FRANK WAS RESPONSIBLE FOR TACTICAL COUNTERMEASURES PROGRAMS. IN 2004, HE WAS PROMOTED TO THE SENIOR EXECUTIVE SERVICE, ASSUMING THE POSITION OF DEPUTY ASSISTANT DIRECTOR FOR PROTECTIVE RESEARCH AND CHIEF TECHNOLOGY OFFICER. FOLLOWING HIS USSS CAREER, FRANK WAS DIRECTOR, PROGRAM MANAGEMENT & LEADERSHIP, FOR THE RAYTHEON COMPANY, AND MORE RECENTLY, WORKED AT LOCKHEED MARTIN'S DEFENSE & INTELLIGENCE SOLUTIONS, RESPONSIBLE FOR PROVIDING OPERATIONS AND INTELLIGENCE ANALYSIS SUPPORT TO THE INTELLIGENCE COMMUNITY. A VETERAN OF THE US NAVY, FRANK HAS A SIGNIFICANT MILITARY AND LAW ENFORCEMENT SPECIAL OPERATIONS BACKGROUND, SERVING AS A SPECIAL WARFARE OPERATOR IN THE NAVY SEALS. AFTER HIS NAVY SERVICE, HE WAS A UNIFORMED PATROL OFFICER WITH THE NORRISTOWN (PA) POLICE DEPARTMENT, A HOMICIDE DETECTIVE WITH THE MONTGOMERY COUNTY (PA) DISTRICT ATTORNEY'S OFFICE, AND A MARYLAND STATE TROOPER-FLIGHT PARAMEDIC. FRANK HOLDS A BA DEGREE IN CRIMINAL JUSTICE AND AN MS DEGREE IN PUBLIC ADMINISTRATION FROM VILLANOVA UNIVERSITY. HE IS THE RECIPIENT OF NUMEROUS AWARDS, INCLUDING THE US SECRET SERVICE AWARD FOR VALOR, THE DEPARTMENT OF THE ARMY'S EXCEPTIONAL CIVILIAN SERVICE AWARD, AND THE SUPERIOR CIVILIAN SERVICE AWARD. BOARD MEMBER, TREASURER, MICHAEL C. SULLIVAN IS THE CHIEF OF STAFF AND HEAD OF EXTERNAL AFFAIRS OF POINT72 ASSET MANAGEMENT. MR. SULLIVAN PREVIOUSLY SERVED AS A SENIOR AIDE IN THE UNITED STATES SENATE, FOCUSING ON TELECOM, TECHNOLOGY, AND FINANCE ISSUES. MR. SULLIVAN ALSO SERVED AS A STAFF MEMBER IN THE U.S. HOUSE OF REPRESENTATIVES WORKING ON SIMILAR ISSUES. BEFORE COMING TO CAPITOL HILL, MR. SULLIVAN WAS THE HEAD OF STRATEGIC DEVELOPMENT FOR A TELECOMMUNICATIONS FOCUSED TRADE ASSOCIATION. MR. SULLIVAN IS INVOLVED WITH SEVERAL VETERANS' MENTAL HEALTH-RELATED NON-PROFIT ORGANIZATIONS. HE HELPED ESTABLISH AND SERVES ON THE BOARD AND AS TREASURER OF THE COHEN VETERANS NETWORK, WHICH OPERATES A NATIONAL NETWORK OF CLINICS TO TREAT VETERANS AND THEIR FAMILY MEMBERS AFFECTED BY POST-TRAUMATIC STRESS. MR. SULLIVAN IS AN ASSOCIATE AT THE NYU-STERN ENDLESS FRONTIER LABS, WHERE HE MENTORS START-UP COMPANIES IN ARTIFICIAL INTELLIGENCE, MACHINE LEARNING, AND RELATED FIELDS. HE IS ALSO A MEMBER OF THE EXECUTIVE COMMITTEE OF STUDENTS FIRST NEW YORK, A NONPROFIT ORGANIZATION ADVOCATING FOR EDUCATIONAL REFORM IN NEW YORK STATE. MR. SULLIVAN IS A GRADUATE OF VANDERBILT UNIVERSITY. BOARD MEMBER, DAVID BIONDI, MD HAS OVER 20 YEARS OF CLINICAL EXPERIENCE IN MEDICAL PRACTICE AND HELD MEDICAL DIRECTORSHIPS AT THE US NAVAL HOSPITAL IN OKINAWA JAPAN, THE PAIN MANAGEMENT PROGRAM & HEADACHE INSTITUTE AT MARYVIEW MEDICAL CENTER IN PORTSMOUTH VA, THE PAIN DIVISION OF THE MICHIGAN HEAD PAIN & NEUROLOGICAL INSTITUTE IN ANN ARBOR MI, AND THE INTERDISCIPLINARY HEADACHE & PAIN REHABILITATION PROGRAM AT SPAULDING REHABILITATION HOSPITAL IN BOSTON MA. HE WAS PREVIOUSLY AN ASSISTANT NEUROLOGIST AT THE MASSACHUSETTS GENERAL HOSPITAL AND AN INSTRUCTOR IN NEUROLOGY AT HARVARD MEDICAL SCHOOL. DR. BIONDI SERVED AS A TRUSTEE FOR THE UNIVERSITY OF NEW ENGLAND AND WAS CHAIR OF ITS ACADEMIC AND RESEARCH AFFAIRS COMMITTEE AND VICE-CHAIR OF ITS LONG-RANGE PLANNING COMMITTEE. HE ALSO SERVED AS A DIRECTOR AND MEDICAL ADVISOR FOR THE AFTER ACTION NETWORK, A NONPROFIT VETERAN SERVICE ORGANIZATION IN KANSAS CITY MO. HE IS A FELLOW OF THE AMERICAN ACADEMY OF NEUROLOGY. DR. BIONDI HAS OVER 15 YEARS OF EXPERIENCE IN CLINICAL RESEARCH AND DEVELOPMENT OF PHARMACEUTICALS AND MEDICAL DEVICES IN THE NEUROLOGY, PSYCHIATRY, AND PAIN THERAPEUTIC AREAS. HIS EXPERIENCES INCLUDE THE DESIGN, IMPLEMENTATION, MONITORING, AND INTERPRETATION OF PHASE 2 TO PHASE 4 CLINICAL TRIALS AND IN-HOUSE AND FIELD-BASED ACTIVITIES ASSOCIATED WITH INSIGHTS GENERATION, NEW BUSINESS OPPORTUNITIES, EMERGING HEALTH POLICY, KNOWLEDGE TRANSLATION AND IMPLEMENTATION, AND ORGANIZATIONAL EFFECTIVENESS. HE PREVIOUSLY SERVED AS EXECUTIVE DIRECTOR FOR CLINICAL PROGRAMS WITH COHEN VETERANS BIOSCIENCE. DR. BIONDI RECEIVED HIS MEDICAL DEGREE FROM THE UNIVERSITY OF NEW ENGLAND, COLLEGE OF OSTEOPATHIC MEDICINE IN BIDDEFORD ME. HE COMPLETED RESIDENCY TRAINING IN NEUROLOGY AT THE NATIONAL NAVAL MEDICAL CENTER IN BETHESDA MD AND IS BOARD-CERTIFIED IN NEUROLOGY WITH SUBSPECIALTY EXPERTISE IN HEADACHE AND PAIN MEDICINE. HE RECEIVED HIS BACHELOR OF SCIENCE - MAGNA CUM LAUDE IN PHARMACY FROM THE LONG ISLAND UNIVERSITY, SCHWARTZ COLLEGE OF PHARMACY & HEALTH SCIENCE IN BROOKLYN NY. BOARD MEMBER, DR. DAVE DEMARCO IS A SENIOR ADVISOR TO C-SUITE LEADERS IN THE LIFE SCIENCES AND HEALTHCARE INDUSTRIES. HE SERVES AS CHIEF STRATEGY OFFICER FOR MATERIAL HEALTH STRATEGIES AND WORKS WITH C-SUITE EXECUTIVES ON GROWTH STRATEGIES AND TEAM PERFORMANCE IN BOTH THE FOR-PROFIT AND NON-FOR-PROFIT INDUSTRIES. HE PREVIOUSLY SERVED AS CHAIR OF THE BOARD OF THE AMERICAN DIABETES ASSOCIATION, LED ERNST & YOUNG'S (EY'S) NORTHEAST LIFE SCIENCES PRACTICE AND WAS THE DEPUTY LEADER OF THE US HEALTHCARE PRACTICE. WITH OVER 25 YEARS OF LEADERSHIP EXPERIENCE, DAVE ADVISES, COACHES AND SHARES INSIGHTS ON STRATEGY AND TRANSFORMATION, COMMERCIAL OPERATIONS, HEALTHCARE POLICY, GOVERNANCE, PUBLIC-PRIVATE-PARTNERSHIPS, AND ENTREPRENEURIAL GROWTH. WHILE SERVING ON THE BOARD OF THE AMERICAN DIABETES ASSOCIATION, HE LED BOARD INITIATIVES INVOLVING: CEO SUCCESSION, PRINCIPAL OFFICER SUCCESSION, BOARD DEVELOPMENT, POLICY CREATION, STRATEGIC PLAN IMPLEMENTATION AND TECHNOLOGY PARTNERSHIPS. DAVE HAS HELD KEY EXECUTIVE POSITIONS, INCLUDING: GLOBAL AESTHETIC FRANCHISE LEADER, SANOFI AVENTIS; US HEALTH DEPUTY LEADER, NORTHEAST REGION LIFE SCIENCES PRACTICE LEADER AND JOHNSON & JOHNSON GLOBAL CLIENT SERVICES PARTNER, EY; RESEARCH SCIENTIST, INTERNAL VENTURE LEADER, AMOCO CHEMICAL; AND COFOUNDER, IDEA CONNECTION SYSTEMS. PART II SECT C LINE 17A FACTS & CIRCUMSTANCES TEST (CONT): DAVE WORKED CLOSELY WITH THE AVENTIS NA LEADERSHIP TEAM TO DEVELOP POST-MERGER INTEGRATION GROWTH STRATEGIES AND LAUNCH KEY BLOCKBUSTER PRODUCTS AIMED AT, AND SUCCEEDING IN, DOUBLING THE SIZE OF THE BUSINESS IN FOUR YEARS. AS A SENIOR PARTNER IN EY'S GLOBAL LIFE SCIENCES TEAM, DAVE PILOTED A NEW P&L ACCOUNTABLE, GO-TO-MARKET MODEL, GROWING THE NORTHEAST PRACTICE AT 30% CAGR, RESULTING IN A $400 MILLION BUSINESS. IN HIS SERVICE TO JOHNSON & JOHNSON, HE PARTNERED WITH J&J LEADERSHIP IN DEVELOPING JANSSEN HEALTHCARE INNOVATION, CHARGED WITH CREATING FUTURE BUSINESS UNITS. DAVE LED THE TRANSFORMATION OF EY'S US HEALTH PRACTICE, RESULTING IN A $750 MILLION BUSINESS. AS A MEMBER OF THE SANOFI AVENTIS NA DERMATOLOGY LEADERSHIP TEAM, DAVE DEVELOPED THE GLOBAL AESTHETIC FRANCHISE STRATEGY AND SERVED AS THE COMMERCIAL HEAD FOR EUROPE. FOR THIS TURNAROUND PROJECT, HE CREATED A PLAN TO TRIPLE EBITDA, IMPLEMENT NEW GLOBAL PRICING POLICIES AND DOUBLE CUSTOMER ACQUISITION. DAVE RECEIVED HIS B.S. FROM GROVE CITY COLLEGE AND PH.D. IN CHEMISTRY FROM PURDUE UNIVERSITY. RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 60000 60000 14019910 14079910 853996 213499 0 0 1000000 1000000 917068 853996 3771064 5656596 90000 90000 120000 60000 360000 250000 250000 229267 213499 942766 1414149 134361 88504 45857 174076 123030 51046 2200047 2128001 72046 168949 OPERATING LEASE RIGHT-OF-USE ASSET 830604 DEPOSITS AND OTHER ASSETS 359755 1190359 OPERATING LEASE LIABILITY 932942 932942 1 UNIVERSITY OF CALIFORNIA SAN DIEGO 9500 GILMAN DRIVE 0940 LA JOLLA CA 920939040 956006144 501(C)3 31373 0 N/A N/A ALCOHOL-PTSD COMORBIDITY: PRECLINICAL STUDIES 1 0 PART I, LINE 2: THE ORGANIZATION REQUIRES GRANTEES TO REGULARLY PROVIDE QUALITATIVE AND QUANTITATIVE REPORTS DESCRIBING HOW FUNDS ARE BEING SPENT AND THE RESULTS THE GRANTEE HAS ACHIEVED. PROGRESS IS MEASURED AGAINST ORIGINAL AND REVISED GRANT PROPOSALS. CONTINUATION OF FUNDING IS DEPENDENT ON RESULTS AND ACCURATE, TIMELY REPORTING. X X X 1 0 0 0 0 0 0 0 0 MAGALI HAAS MD PHD FORMER CEO 497238 0 0 0 0 0 14911 0 0 0 512149 0 0 0 ALLYSON GAGE PHD FORMER CHIEF MEDICAL OFFICER 396239 0 0 0 0 0 18318 0 11667 0 426224 0 0 0 LEE LANCASHIRE FORMER CHIEF INFORMATION OFFICER 244211 0 86584 0 0 0 13232 0 58038 0 402065 0 0 0 PETER HOEHN FORMER CHIEF EXECUTIVE OFFICER 345622 0 0 0 0 0 19800 0 22261 0 387683 0 0 0 NICOLE HARMON FORMER PRESIDENT 293027 0 0 0 0 0 12984 0 33056 0 339067 0 0 0 EVGENY RAKHMATULIN FORMER CHIEF TECHNOLOGY OFFICER 250919 0 0 0 0 0 15745 0 33056 0 299720 0 0 0 RAGINI VERMA FORMER HEAD OF BIOMAKERS & CLINICAL 256653 0 0 0 0 0 14861 0 10665 0 282179 0 0 0 MARYAN ZIRKLE FORMER EXECUTIVE DIRECTOR, BRAINCOMM 245635 0 0 0 0 0 14860 0 11667 0 272162 0 0 0 LAUREN GOLDSMITH FORMER SENIOR DIRECTOR, CONTRACTS & 236242 0 2000 0 0 0 13959 0 11667 0 263868 0 0 0 MARK ZERVAS FORMER HEAD OF DISCOVERY AND PRECLIN 206998 0 0 0 0 0 12750 0 33056 0 252804 0 0 0 MICHAEL CARSON FORMER HEAD OF COMMUNICATIONS 211087 0 0 0 0 0 0 0 21937 0 233024 0 0 0 PART I, LINE 4A THE ORGANIZATION HAS A SEVERANCE AGREEMENT WITH ITS TOP MANAGEMENT OFFICIAL, MAGALIE HAAS, BUT MADE NO PAYMENTS DURING THE TAX YEAR. THE SEVERANCE AGREEMENT PROVIDES THAT SHE WILL BE PAID 16 WEEKS OF HER SALARY AT HER CURRENT BASE RATE. THE AGREEMENT IS AFFECTIVE JUNE 24, 2024. THE ORGANIZATION ALSO HAD A SEVERANCE AGREEMENT WITH PETER HOEHN, ANOTHER TOP MANAGEMENT OFFICIAL. THE SEVERANCE AGREEMENT PROVIDED THAT HE WOULD BE PAID 8 WEEKS OF HIS SALARY AT HIS CURRENT BASE RATE. WHILE NO PAYMENTS WERE MADE DURING THE TAX YEAR, TWO WEEKS OF HIS SEVERANCE WERE ACCRUED AS WAGES IN THE FISCAL YEAR FILING. FORM 990, PART III, LINE 3 THE BOARD OF DIRECTORS INITIATED A WIND DOWN OF OPERATIONS IN JUNE 2024. FORM 990, PART VI, SECTION B, LINE 11B THE FORM 990 WAS REVIEWED BY THE ORGANIZATION'S OUTSOURCED CFO AND THEN REVIEWED, AUTHORIZED AND SIGNED BY THE ORGANIZATION'S CEO & PRESIDENT. FORM 990, PART VI, SECTION B, LINE 12C THE BOARD OF DIRECTORS REQUIRES AN ANNUAL DECLARATION FROM ALL BOARD MEMBERS AND SENIOR MANAGEMENT AS TO THE EXISTENCE AND DISCLOSURE OF ANY POTENTIAL CONFLICTS OF INTEREST. THE BOARD MEMBERS SIGN A DISCLOSURE STATEMENT. ANY POTENTIAL CONFLICTS ARE DISCUSSED BY THE DIS-INTERESTED BOARD MEMBERS, WHILE THE PARTY IN POTENTIAL CONFLICT IS REQUIRED TO LEAVE THE ROOM. BOARD MEETING MINUTES WILL DOCUMENT THE DISCUSSION AND DECISION MAKING PROCESS. IN THE EVENT OF A POTENTIAL CONFLICT, PROCEDURES TO OBTAIN COMPETITIVE BIDS AND DILIGENCE ON FAIR MARKET VALUE WILL BE ESTABLISHED. FORM 990, PART VI, SECTION B, LINE 15 CVB'S EXECUTIVE COMPENSATION PROGRAM IS ADMINISTERED BY THE BOARD OF DIRECTORS. THE BOARD IS RESPONSIBLE FOR ESTABLISHING AND MAINTAINING A COMPETITIVE COMPENSATION PROGRAM FOR THE KEY EXECUTIVES OF THE ORGANIZATION. THE BOARD MEETS AS NEEDED TO REVIEW THE COMPENSATION PROGRAM AND MAKE RECOMMENDATIONS FOR ANY CHANGES, AS APPROPRIATE. A PERFORMANCE EVALUATION IS CONDUCTED AND REVIEWED EACH YEAR AND IS INTENDED TO ENSURE THAT THE COMPENSATION PROGRAM FALLS WITHIN A REASONABLE RANGE OF COMPETITIVE PRACTICES FOR COMPARABLE POSITIONS AMONG SIMILARLY SITUATED ORGANIZATIONS. FOLLOWING THIS REVIEW, THE BOARD REVIEWS AND APPROVES, FOR SELECTED KEY EXECUTIVES, BASE SALARIES AND ANNUAL INCENTIVE OPPORTUNITY ADJUSTMENTS, AND OBJECTIVES AND GOALS UPCOMING YEAR'S ANNUAL INCENTIVE PLAN. THE BOARD REVIEWS AND RECOMMENDS TO THE BOARD SALARY APPROVAL AND INCENTIVE AWARDS FOR THE CEO/PRESIDENT AND SELECTED KEY SENIOR STAFF. FORM 990, PART VI, SECTION C, LINE 19 UPON REQUEST AND FORMS AVAILABLE THROUGH CHARITY NAVIGATOR WEBSITE AS WELL. FORM 990, PART IX, LINE 11G OTHER PROFESSIONAL FEES: PROGRAM SERVICE EXPENSES 0. MANAGEMENT AND GENERAL EXPENSES 182,247. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 182,247. RESEARCH COLLABORATION EXPENSES: PROGRAM SERVICE EXPENSES 69,107. MANAGEMENT AND GENERAL EXPENSES 0. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 69,107. CONTRACTED SERVICES: PROGRAM SERVICE EXPENSES 1,971,037. MANAGEMENT AND GENERAL EXPENSES 89,881. FUNDRAISING EXPENSES 19,295. TOTAL EXPENSES 2,080,213. FORM 990, PART XI, LINE 9: CHANGE IN FUTURE GRANT OBLIGATIONS IMPARIMENT LOSS -1,185,264. LOSS ON CANCELED GRANTS AND RELEASE OF COMMITTMENTS -1,032,839. PART XII, LINE 2B THE FISCAL YEAR ENDING 6-30-24 WILL BE INCLUDED IN AN 18-MONTH AUDIT FOR THE PERIOD ENDING DECEMBER 31, 2024. EARLY SIGNAL LLC 251 LITTLE FALLS DRIVE WILMINGTON DE 19808 TO HOLD INTELLECTUAL PROPERTY DE 0 0 COHEN VETERANS BIOSCIENCE INC BRAINCOMMONS LLC 251 LITTLE FALLS DRIVE WILMINGTON DE 19808 TO HOLD INTELLECTUAL PROPERTY DE 0 0 COHEN VETERANS BIOSCIENCE INC